

Участие в международни проекти и съавторство в международни препоръки

1. Публикация EURIPID Guidance Document on External Reference Pricing (ERP) Updated Version November 2025; Authors: **Mariya Vasileva (NCPRMP)** **Yoana Velcheva (NCPRMP)** Stefan Fischer (GÖG) Peter Schneider (GÖG) Gergely Németh (NEAK) Elżbieta Kuriata (AOTMiT) Kasper Mucha (AOTMiT) Aleksandra Pelczarska (AOTMiT) Contributors Anja Sonemann (RIZIV-INAMI) Simona Magajna (JAZMP) Nejc Bakovnik (JAZMP) Sónia Caldeira (Infarmed)

Участие на НСЦРЛП в европейски проект „Разработване на функции за ранно предупреждение и насоки в областта на ценообразуването чрез базата данни EURIPID“ (Project 101100610 – EURIPID, EU4H-2022-PJ Тема: EU4H-2022-PJ-08), финансиран от Европейския съюз и финализиран с актуализирано Ръководство „Насоки на EURIPID за външно референтно ценообразуване“ Актуализацията на ръководството беше ръководена от Националния съвет по цени и реимбурсиране на лекарствените продукти (НСЦРЛП) на България, в тясно сътрудничество с партньорските институции от Унгария (NEAK), Австрия (Gesundheit Österreich GmbH), Полша (AOTMiT), Белгия (RIZIV-INAMI), Словения (Javna agencija Republike Slovenije za zdravila in medicinske pripomočke) и Португалия (INFARMED).

Публикации на НСЦРЛП, свързани с политиките на ценообразуване, реимбурсиране, оценка на здравните технологии и проследяване на ефекта от терапията с лекарствени продукти в индексирани и реферирани научни списания с импакт фактор и периодични издания

2. **Manoela Manova, Boryana Ivanova**, Rositsa Krasteva, Nikolay Conev, Tanya Zlatanova, Jeli azko Arabadjiev, Natalia Chilingirova, Mila Petrova, Assen Dudov, Bozhil Robev, Velko Minchev, Ivan Tonev, Krassimir Koynov, Daniel Penchev, Todor Georgiev, **Antoan Rangelov, Alexandra Savova**. (2026). Real-World Evidence of Atezolizumab Efficacy as Part of First-Line Treatment for Extensive-Stage SCLC in Bulgaria. *Cancers*, 18(7), 1129.
3. **Antoan Rangelov, Boryana Ivanova, Manoela Manova**, Galya Kondeva, **Alexandra Savova**. (2026). Real-world effectiveness of Ruxolitinib: analysis and comparison with COMFORT-II. *Pharmacia*, 73, 1-7.

4. **Manoela Manova, Boryana Ivanova, Jeli azko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Zornitsa Katrandzhieva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Alexandra Savova.** Real-world evidence of first-line osimertinib effectiveness in Bulgarian patients: a retrospective analysis. Expert Review of Pharmacoeconomics & Outcomes Research 25.8 (2025): 1231-1237.
5. **Alexandra Savova, Boryana Ivanova, Gergana Shalamanova, Iva Gavrilova, Jeli azko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Martina Nacheva, Lyubomir Bakalivanov, Boryana Zidarova, Dimitrina Apostolova, Mariya Vasileva, Silvia Terezova, Manoela Manova.** (2024). Real-world effectiveness of dabrafenib and trametinib in patients with BRAF-positive melanoma treated in routine Bulgarian clinical practice. Pharmacia, 71, 1-11.
6. **Manoela Manova, Jeli azko Arabadjiev, Radoslav Mangaldzhiev, Assen Dudov, Daniel Penchev, Margit Hemetsberger, Arkadi Sharkov, Boryana Zidarova, Dimitrina Apostolova, Maria Vasileva, Silvia Terezova, Mila Vlaskovska, Alexandra Savova.** Adequate effectiveness of ribociclib plus letrozole or fulvestrant in patients with advanced or metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated in routine Bulgarian clinical practice. (2023) Biotechnology & Biotechnological Equipment, 37(1), 2268753.
7. **Boryana Zidarova, Dimitrina Apostolova, Alexandra Savova, Manoela Manova, Silvia Terezova, Maria Vasileva, Nikolay Danchev.** LEGAL STATUS OF THE NATIONAL COUNCIL ON PRICES AND REIMBURSEMENT OF MEDICINAL PRODUCTS AND ITS PLACE IN THE HEALTH CARE SYSTEM. ИНФРАСТРУКТУРАТА И КОМУНИКАЦИИТЕ ПРЕЗ 21 ВЕК, май 2017, кн. 11-12
8. **Боряна Зидарова, Димитрина Апостолова.** Предизвикателствата пред регламента за оценка на здравните технологии. Капитал здраве, юни 2020
9. **Боряна Зидарова, Димитрина Апостолова, Александра Савова, Маноела Манова, Силвия Терезова, Мария Василева.** България по пътя на медицината, основана на доказателства при лечението с лекарствени продукти. Капитал здраве, декември 2022
10. **Боряна Иванова, Александра Савова, Маноела Манова, Силвия Терезова, Любомир Бакаливанов, Мария Василева, Димитрина**

Апостолова, Боряна Зидарова. България продължава по пътя на медицината, основана на доказателства. Капитал здраве, декември 2023

11. **B Ivanova, A Savova, L Bakalivanov, B Zidarova, D Apostolova, M Vasileva, S Terezova, M Manova** (2024) RWD121 Real World PFS Outcomes of Bulgarian Patients With BRAF-Positive Melanoma Treated With Dabrafenib and Trametinib. Value in Health 27 (12), S596
12. **Silvia Terezova, Mariya Vasileva**, 2023. "Expenditures For Medicines, Paid By NHIF In Accordance With The Health Insurance Law - Status And Trends," Conferences of the department "Economics and Management of Trade", Publishing house "Science and Economics" Varna, issue 1, pages 107-113.
13. **A. Savova, Z. Mitkova, B. Zidarova, M. Vasileva, M. Manova, N. Danchev.** Analysis of the changes in reference value, paid with public funds after exclusion of medicinal products from positive drug list. VI th national pharmaceutical congress with international participation, October 2016
14. **Vasileva M, Manova M, Marik V, Zidarova B, Apostolova D, Terezova S, Savova A, Danchev N.** (2015) External and internal reference pricing as cost containment measures in bulgaria. Value in Health, 18, A336.
15. **Savova, A., Stoimenova, A., Manova, M., Zidarova, B., Petrova, G., Danchev, N.** (2015). Pharmacoeconomic Guideline for Positive Drug List Application Purposes Implemented in Bulgaria. Value in Health, 18(7), A548.
16. **Антоан Рангелов, Боряна Иванова, Маноела Манова, Александра Савова** (2025) доклад на тема „Роля на НСЦРЛП в прилагането на Регламент (2021/2282) за оценка на здравните технологии на национално и европейско ниво“. IX Конгрес по фармация с международно участие PharmaceuticAI Science Revolution, 30.10-02.11.2025 г.
17. **Antoan Rangelov, Boryana Ivanova, Manoela Manova, Alexandra Savova,** (2025) Comparative data analysis from the ruxolitinib use in real clinical practice and the clinical trial COMFORT-II. IX Конгрес по фармация с международно участие PharmaceuticAI Science Revolution, 30.10-02.11.2025 г.
18. **Boryana Ivanova, Alexandra Savova, Manoela Manova** (2025) Health technology assessments of gene therapies in four european countries – United Kingdom, France, Germany and Sweden. IX Конгрес по фармация с международно участие PharmaceuticAI Science Revolution, 30.10-02.11.2025 г.

19. **Boryana Ivanova**, Gergana Petrova, **Antoan Rangelov**, **Manoela Manova**, **Aleksandra Savova** (2025) Real-world outcomes of bulgarian patients with cystic fibrosis treated with ivacaftor/tezacaftor/elexacaftor in a combination regimen with ivacaftor. IX Конгрес по фармация с международно участие PharmaceuticAI Science Revolution, 30.10-02.11.2025 г.
20. **Antoan Rangelov**, Lyubomir Marinov, Iva Parvova, Emil Hristov, Georgi Momekov, Boris Kadinov (2025) Study of the cardiovascular toxicity of tofacitinib and baricitinib in vitro and in vivo. IX Конгрес по фармация с международно участие PharmaceuticAI Science Revolution, 30.10-02.11.2025 г.
21. **Б.Иванова**, **А.Савова**, **М.Манова** (2023) Разрешени за употреба генни терапии в Европейския съюз. VIII-ми Конгрес по фармация с международно участие Escape from the Pandemonium: Pharmaceutical Restart 2023

II. Публикации на членове на НСЦРЛП в индексирани и реферирани научни списания, в съавторство с международни и национални научни колективи

22. **Manova M**, **Savova A**, **Vasileva M**, **Terezova S**, Kamusheva M, Grekova D, Petkova V and Petrova G (2018) Comparative Price Analysis of Biological Products for Treatment of Rheumatoid Arthritis. Front. Pharmacol. 9:1070. doi: 10.3389/fphar.2018.01070
23. Kawalec P, Tesar T, Vostalova L, Draganic P, **Manova M**, **Savova A**, Petrova G, Rugaja Z, Männik A, Sowada C, Stawowczyk E, Harsanyi A, Inotai A, Turcu-Stiolica A, Gulbinovič J and Pilc A (2017) Pharmaceutical Regulation in Central and Eastern European Countries: A Current Review. Front. Pharmacol. 8:892. doi: 10.3389/fphar.2017.00892
24. Mitkova Z, **Manova M**, **Vasileva M**, **Zidarova B**, **Apostolova D**, **Savova A**. Influence of regulatory measures and market policy for reimbursed medicinal products on the value, paid with public funds in Bulgaria in 2015. World Journal of Pharmacy and Pharmaceutical Sciences. 6 (6): 19-31, 2017
25. Kamusheva, M., Tachkov, K., Petrova, G., **Savova, A.**, & **Manova, M.** (2018). Orphan medicinal products' access to the Bulgarian pharmaceutical market – challenges and obstacles. Expert Opinion on Orphan Drugs, 6(2), 95–104
26. Kamusheva M, **Vassileva M**, **Savova A**, **Manova M** and Petrova G (2018) An Overview of the Reimbursement Decision-Making Processes in Bulgaria As a

- Reference Country for the Middle-Income European Countries. *Front. Public Health* 6:61. doi: 10.3389/fpubh.2018.00061
27. Marcell Csanadi , Zoltan Kalo , Christian PJ Prins , Eszter Grelinger , Anna Kiss , Frank-Ulrich Fricke , Leos Fuksa , Tomas Tesar , **Manoela Manova** , Laszlo Lorenzovici , Zoltan Voko , Louis P. Garrison. The implications of external price referencing on pharmaceutical list prices in Europe, *Health Policy and Technology* (2018)
 28. Kamusheva M, **Manova M**, **Savova AT**, Petrova GI, Mitov K, Harsányi A, et al. Comparative analysis of legislative requirements about patients' access to biotechnological drugs for rare diseases in Central and Eastern European Countries. *Front Pharmacol.* 2018;9:795.
 29. Mitkova, Z., **Vasileva, M., Savova, A., Manova, M.,** & Petrova, G. (2016). Analysis of cardiovascular medicines prices and reimbursement in Bulgaria and Romania. *Rev. Farm*, 64, 633-642
 30. Mitkova, Z., **Manova, M., Savova, A.,** Peneva, A., Mitkov, J., Tkachova, O. V., Petrova, G. (2018). Statins utilization and price variations-comparison between Ukraine and Bulgaria.
 31. Zornitsa Mitkova, Konstantin Mitov, Vasil Valov, **Manoela Manova, Alexandra Savova**, Maria Kamusheva, Dimitar Tcharaktchiev, Zhivko Angelov, Galia Angelova, Guenka Petrova. (2018). Medical, social, and economic consequences of type 2 diabetes therapy with medicinal products from the group of DPP-4i, SGLT-2i, and GLP-1 RA. *International Journal of Diabetes in Developing Countries*, 38(4), 520-521
 32. Oksana Tkachova, Larysa Iakovlieva, Zornitsa Mitkova, **Manoela Manova, Alexandra Savova**, Guenka Petrova. (2019). An affordability of statins therapy-comparative analysis between Ukraine and Bulgaria. *BMC Health Services Research*, 19(1), 902.
 33. **Vassileva, M.,** Kamusheva, M., **Manova, M., Savova, A.,** Tachkov, K., & Petrova, G. (2019). Historical overview of regulatory framework development on pricing and reimbursement of medicines in Bulgaria. *Expert Review of Pharmacoeconomics & Outcomes Research*, 19(6), 733–742.
 34. Malinowski KP, Kawalec P, Trąbka W, Czech M, Petrova G, **Manova M, Savova A,** Draganić P, Vostalová L, Slabý J, Männik A, Márky K, Rugaja Z, Gulbinovic J, Tesar T and Paveliu MS (2019) Reimbursement Legislations and Decision Making

- for Orphan Drugs in Central and Eastern European Countries. *Front. Pharmacol.* 10:487.
35. Zornitsa Mitkova, Konstantin Mitov, Vasil Valov, **Manoela Manova**, **Alexandra Savova**, Maria Kamusheva, Dimitar Tcharaktchiev, Zhivko Angelov, Galia Angelova, Guenka Petrova. (2019). Incretins and SGLT-2i Therapy of Type 2 Diabetes—Real Life Study of Their Therapeutic and Economic Effects. *Frontiers in Pharmacology*, 10, 364
 36. Konstantin Tachkov, Konstantin Mitov, Zornitsa Mitkova, Maria Kamusheva, Maria Dimitrova, Valentina Petkova, **Alexandra Savova**, Miglena Doneva, Dimitar Tcarukciev, Vasil Valov, Galia Angelova, **Manoela Manova**, Guenka Petrova. (2019). Improved quality of diabetes control reduces complication costs in Bulgaria. *Biotechnology & Biotechnological Equipment*, 33(1), 814-820.
 37. Konstantin Tachkov, Maria Dimitrova, Konstantin Mitov, **Alexandra Savova**, Maria Kamusheva, Jordan Dimitrov, **Manoela Manova**, Daniela Grekova, Valentina Petkova. (2019). Micro and macro analysis on the burden of COPD hospitalizations on the Bulgarian healthcare system. *Biotechnology & Biotechnological Equipment*, 33(1), 1–11
 38. Mitov K, Mitkova Z, Tashkov K., **Manova M.**, Kamusheva M., Dimitrova M., Petkova V, **Savova A.**, Doneva M., Charakchiev D., Zaharieva S., Valov V., Angelova G., Petrova G. The diabetes mellitus morbidity, complications and control in Bulgaria. *2019 General Medicine* 21 (2) 16-23
 39. Krzysztof Piotr Malinowski, Paweł Kawalec, Wojciech Trąbka, Christoph Sowada, Guenka Petrova, **Manoela Manova**, **Alexandra Savova**, Pero Draganić, Juraj Slabý, Agnes Männik, Kristóf Márky, Zinta Rugaja, Jolanta Gulbinovic, Tomas Tesar, Marian Sorin Paveliu. (2020). Health technology assessment and reimbursement policy for oncology orphan drugs in Central and Eastern Europe. *Orphanet journal of rare diseases*, 15(1), 277.
 40. Mitkova Z, **Vasileva M**, **Savova A**, **Manova M**, **Terezova S** and Petrova G (2020) Comparison of Cardiovascular Medicines Prices in Four European Countries. *Front. Public Health* 8:433.
 41. Zemplényi A, Tachkov K, Balkanyi L, Németh B, Petykó ZI, Petrova G, Czech M, Dawoud D, Goettsch W, Gutierrez Ibarluzea I, Hren R, Knies S, Lorenzovici L, Maravic Z, Piniazhko O, **Savova A**, **Manova M**, Tesar T, Zerovnik S and Kaló Z

- (2023) Recommendations to overcome barriers to the use of artificial intelligence-driven evidence in health technology assessment. *Front. Public Health* 11:1088121.
42. Jakab I, Dimitrova M, Houžez F, Bereczky T, Fövényes M, Maravic Z, Belina I, Andricuic C, Tóth K, Piniashko O, Hren R, Gutierrez-Ibarluzea I, Czech M, Tesar T, Niewada M, Lorenzovici L, Kamusheva M, **Manova M**, **Savova A**, Mitkova Z, Tachkov K, Németh B, Petykó ZI, Dawoud D, Delnoij D, Knies S, Goettsch W and Kaló Z (2023) Recommendations for patient involvement in health technology assessment in Central and Eastern European countries. *Front. Public Health* 11:1176200. doi: 10.3389/fpubh.2023.1176200
 43. Tachkov, K., **Savova, A.**, **Manova, M.**, & Petrova, G. (2023). Tackling reimbursement challenges to fair access to medicines – introduction to the topic. *Expert Review of Pharmacoeconomics & Outcomes Research*, 23(6), 597–606
 44. **Manoela Manova**, Zornitsa Emilova Mitkova, **Alexandra Savova**, Anna Borisova, Lily Peikova, Javor Mitkov, Guenka Petrova. (2023). Impact of generics competition on prices and utilization of antiepileptic medicines in Bulgaria. *Journal of Applied Pharmaceutical Science*, 13(5), 066-072.
 45. Konstantin Tachkov, Francisco Somolinos-Simón, Jose Tapia-Galisteo, Maria Elena Hernando, Gema García-Sáez, Maria Dimitrova, Maria Kamusheva, Zornitsa Mitkova, Zsuzsanna Petyko, Bertalan Nemeth, Zoltan Kalo, Tomas Tesar, Marian-Sorin Paveliu, Oresta Piniashko, Iga Lipska, Adina Turcu-Stiolica, **Alexandra Savova**, **Manoela Manova**, Rok Hren, Petra Došenović Bonča, Saskia Knies, Michal Stanak, Tomáš Doležal, Dinko Vitezic, Guenka Petrova. (2024). Transferability of new methods for health technology assessment in the field of diabetes between early and late adopters' countries. *Biotechnology & Biotechnological Equipment*, 38(1).
 46. **Savova, A.**, **Manova, M.**, Tachkov, K., & Petrova, G. (2024). The role of insurance policies in the drug pricing landscape. *Expert Review of Pharmacoeconomics & Outcomes Research*, 24(2), 189–202.
 47. Mariyana Eneva, **Petya Borisova**, **Boryana Ivanova**, Mila Petrova, **Alexandra Savova**, **Manoela Manova**. (2026). Effectiveness of ribociclib in metastatic breast cancer in one hospital in Bulgaria—results from real-world clinical practice. *Pharmacia*, 73, 1-9

48. Z Mitkova, **M Manova**, **A Savova**, A Stoimenova, G Petrova. (2016) Generic competition and its impact on reference pricing system and medicines utilization in the group of sartans Value in Health 20 (9), A628
49. Zornitsa Mitkova, Violeta Angelova, Antonia Tsvetkova, Zoya Stamova, **Manoela Manova**, Guenka Ivanova Petrova. (2025) Impact Of Reimbursement Policy On Medicines Expenditures And Copayment: The Case of Cardiovascular Medicines In Bulgaria. Value in Health 28 (12), S343
50. Z Mitkova, E Diyanova, V Hristakieva, **M Manova**. (2024) The Impact of First Generic Entrance on Public Spending and Medicines Cost: A Case Study in Bulgaria. Value in Health 27 (12), S285
51. I Haygarova, A Turcu-Stiolica, MS Subtirelu, N Karalazou, I Paliu, N Ganov, M Pesheva, **A Savova**, G Petrova, **M Manova**, **B Ivanova**, M Kamusheva. (2023) „Analysis of the Access to Medicines for Rare Diseases in Countries from the Balkan Peninsula: A Comparative Analysis“ Value in Health, 20(26), S291-S292
52. Z Mitkova, **A Savova**, **M Manova**, **M Vasileva**, **S Terezova**, G Petrova (2023) PCV95 ANALYSIS OF ACE-INHIBITORS PRICES IN FOUR EUROPEAN COUNTRIES. Value in Health 22, S559
53. **B Ivanova**, A Turcu-Stiolica, **M Manova**, J Gierczyński, MS Naidin, **A Savova**, M Czech, G Petrova, M Kamusheva. (2024) HTA342 Do HTA Process in Central and Eastern Europe Countries Improve the Availability and Accessibility of Advanced Therapies: A 3-Year Analysis for Bulgaria, Romania, and Poland. Value in Health 27 (12), S422-S423
54. Monica M, Becirovic S, Bianchi-Manaila I, Duborija-Kovacevic N, Draganic P, Garouliene K, Hammerman A, Ispan F, **Ivanova B**, Männik A, Meresz G, Nazaryan L, Oleshchuk O, **Savova A**, Skoupa J, Stefanovic N, Tesar T and Kawalec P (2025) EUROCOVER-CLL: Reimbursement and accessibility of new treatments in relapsed/refractory chronic lymphocytic leukemia. Front. Pharmacol. 16:1629465. doi: 10.3389/fphar.2025.1629465
55. Holownia-Voloskova M, Chitan E, Piniashko O, **Rangelov A**, Obrzut G. (2025) HPR114 How Health Policy Influences HTA Outcomes: Comparative Insights From Ukraine, Moldova, and Bulgaria. Value in Health, 28S343